Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levosimendan - AbbVie/Tenax Therapeutics

Next Previous
X
Search
Drug Profile

Levosimendan - AbbVie/Tenax Therapeutics

Alternative Names: Daxim; ODM 109; OR-1259; Simdax; TNX-101; TNX-102 - Tenax Therapeutics; TNX-103; TNX102

Latest Information Update: 08 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orion
  • Developer Abbott Laboratories; AbbVie; Imperial College of Science, Technology and Medicine; Orion; Tenax Therapeutics; Yooyoung Pharmaceutical
  • Class Antiarrhythmics; Cardiotonics; Cardiovascular therapies; Hydrazones; Nitriles; Pyridazines; Small molecules; Vasodilators
  • Mechanism of Action Calcium binding protein modulators; Calcium-sensitising phosphodiesterase inhibitors; Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Phase III Amyotrophic lateral sclerosis; Chronic heart failure; Low cardiac output; Pulmonary hypertension
  • Discontinued Myocardial infarction; Septic shock; Stroke; Transient ischaemic attacks

Most Recent Events

  • 30 Apr 2024 Tenax Therapeutics has protection for use of levosimendan in Pulmonary hypertension with heart failure with preserved ejection fraction in USA
  • 20 Feb 2024 Oral levosimendan licensed to Tenax Therapeutics through expanded license agreement with Orion Corporation for Pulmonary hypertension associated with heart failure and preserved ejection fraction Worldwide
  • 07 Feb 2024 USPTO grants Notice of Allowance for use of levosimendan in Pulmonary hypertension with heart failure with preserved ejection fraction in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top